ストックスクリーナーアプリを入手
1.715
1.44%
-0.025
前日終値:
$1.74
開ける：
$1.75
24時間の取引高:
245.85K
Relative Volume:
0.13
時価総額：
$395.01M
収益：
$8.95M
当期純損益:
$-21.49M
株価収益率:
-14.29
EPS:
-0.12
ネットキャッシュフロー:
$-29.24M
1週間 パフォーマンス:
-2.56%
1か月 パフォーマンス:
-5.77%
6か月 パフォーマンス:
+161.04%
1年 パフォーマンス:
+200.25%
1日の値動き範囲:
$1.7005
$1.75
1週間の範囲:
$1.57
$1.7555
52週間の値動き範囲:
$0.3651
$2.09
Lineage Cell Therapeutics Inc Stock (LCTX) Company Profile
名前
Lineage Cell Therapeutics Inc
セクター
電話
510-871-4188
住所
2173 Salk Avenue, Suite 200, Carlsbad, CA
LCTX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
LCTX
Lineage Cell Therapeutics Inc
|
1.715 | 400.77M | 8.95M | -21.49M | -29.24M | -0.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.82 | 116.04B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
720.13 | 75.97B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.86 | 61.48B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
896.32 | 56.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
203.47 | 43.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
Lineage Cell Therapeutics Inc Stock (LCTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-08-20 | 開始されました | Craig Hallum | Buy |
| 2022-11-02 | 開始されました | Robert W. Baird | Outperform |
| 2022-06-14 | 開始されました | B. Riley Securities | Buy |
| 2021-08-19 | 開始されました | Noble Capital Markets | Outperform |
| 2021-03-31 | 開始されました | Cantor Fitzgerald | Overweight |
Lineage Cell Therapeutics Inc (LCTX) 最新ニュース
How Lineage Cell Therapeutics Inc. stock valuation compares with sector2025 Historical Comparison & Smart Investment Allocation Tips - Newser
What insider trading reveals about Lineage Cell Therapeutics Inc. stockSell Signal & Daily Growth Stock Tips - Newser
Is Lineage Cell Therapeutics Inc. stock a smart buy before Fed meetingJuly 2025 Short Interest & AI Optimized Trading Strategy Guides - Newser
How Lineage Cell Therapeutics Inc. stock performs during market turbulence2025 Top Decliners & Safe Swing Trade Setups - Newser
How currency fluctuations impact Lineage Cell Therapeutics Inc. stockPortfolio Value Summary & Accurate Intraday Trade Tips - Newser
Is Lineage Cell Therapeutics Inc. stock safe for risk averse investorsCEO Change & Daily Stock Trend Reports - Newser
Is Lineage Cell Therapeutics Inc. stock attractive for growth ETFsPortfolio Gains Summary & Free Expert Verified Stock Movement Alerts - Newser
Is Lineage Cell Therapeutics Inc. stock cheap by valuation metricsJuly 2025 Review & Entry Point Confirmation Alerts - Newser
Is Lineage Cell Therapeutics Inc. stock expanding market penetrationMarket Growth Report & Technical Entry and Exit Alerts - Newser
Will Lineage Cell Therapeutics Inc. stock beat international competitionJuly 2025 Action & Precise Swing Trade Entry Alerts - Newser
An analyst sees good growth prospects for Lineage Cell Therapeutics Inc (LCTX) - Setenews
Is Lineage Cell Therapeutics Inc. stock a buy on weaknessTreasury Yields & Long-Term Growth Plans - Newser
Can Lineage Cell Therapeutics Inc. stock weather global recession2025 Winners & Losers & Technical Pattern Based Buy Signals - Newser
Lineage Cell Therapeutics withdraws CIRM grant application, plans resubmission By Investing.com - Investing.com Australia
Lineage Therap Withdraws CIRM Grant Application - TipRanks
Lineage Cell Therapeutics Inc withdrew CIRM grant application filed in June 2025SEC filing - marketscreener.com
Lineage Cell Therapeutics withdraws CIRM grant application, plans resubmission - Investing.com
Lineage Cell Therapeutics Withdraws CIRM Grant Application - TradingView
Lineage Cell Therapeutics (LCTX) pulls CIRM CLIN2 grant application, plans OPC1 resubmission - Stock Titan
What analysts say about Lineage Cell Therapeutics Inc stockLong-Term Investment Plans & Small Capital Portfolio Tips - earlytimes.in
Does Tuni Textile Mills Limited Have Competitive Moats for LongTerm GrowthDividend Yield Trends & Superior Wealth Strategies - earlytimes.in
Can Shri Jagdamba Polymers Limited Deliver Stable Cash Flow in Market DownturnsRisk-Reward Ratio Analysis & Fast Profit Portfolio Plans - earlytimes.in
Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Earns Buy Rating from D. Boral Capital - Defense World
Lineage Cell says first OpRegen development milestone under Roche pact achieved - MSN
This trade activity should not be overlooked: Lineage Cell Therapeutics Inc (LCTX) - Setenews
D. Boral Capital Maintains Lineage Cell Therapeutics (LCTX) Buy Recommendation - Nasdaq
Lineage Cell Therapeutics explores future of dry AMD treatment - Traders Union
LCTX: D. Boral Capital Maintains 'Buy' Rating with $2.00 Price T - GuruFocus
HC Wainwright & Co. Maintains Lineage Cell Therapeutics (LCTX) Buy Recommendation - Nasdaq
HC Wainwright & Co. Maintains Buy Rating for LCTX with $9 Target - GuruFocus
Lineage Therap Secures $5M Milestone Payment - TipRanks
Lineage Cell Therapeutics : Achieves First Milestone Under Worldwide Collaboration Agreement with Genentech - MarketScreener
[8-K] Lineage Cell Therapeutics, Inc. Reports Material Event | LCTX SEC FilingForm 8-K - Stock Titan
Lineage Cell Therapeutics Q3 2025 Earnings Preview - MSN
Why Lineage Cell Therapeutics Inc. stock is popular among millennialsTrade Risk Assessment & Daily Risk Controlled Trade Plans - newser.com
Is Lineage Cell Therapeutics Inc. stock a buy before product launches2025 Valuation Update & Long-Term Growth Stock Strategies - newser.com
Will Lineage Cell Therapeutics Inc. stock test record highs in 20252025 Support & Resistance & Risk Managed Investment Strategies - newser.com
Why Lineage Cell Therapeutics Inc. stock could see breakout soon2025 Trading Recap & Technical Entry and Exit Alerts - newser.com
Forecasting Lineage Cell Therapeutics Inc. price range with options dataJuly 2025 Highlights & Low Risk Entry Point Tips - newser.com
How Lineage Cell Therapeutics Inc. stock reacts to oil pricesPortfolio Return Report & Entry and Exit Point Strategies - newser.com
Is Lineage Cell Therapeutics Inc. stock a momentum leader - newser.com
Lineage Cell Therapeutics Inc (LCTX) 財務データ
収益
当期純利益
現金流量
EPS
0.05%
0.90%
大文字化:
|
ボリューム (24 時間):